Avid Bioservices Announces Grand Opening of New Early-Phase Center of Excellence Facility. Read the Release

All Resources

Seamless Onshoring from China-Based CDMO to Avid Bioservices

April 8, 2026

Onshoring with Confidence

A Seamless Transition from a China-Based CDMO to U.S. Manufacturing

Facing rising geopolitical risk, evolving regulatory considerations, and investor pressure to onshore, a U.S.-based biotech company needed to relocate its clinical-stage biologics manufacturing program without disrupting development timelines or product supply.

Partnering with Avid Bioservices, the sponsor successfully executed a rapid, high-fidelity transfer of its Phase I monoclonal antibody program to a trusted U.S. facility, ensuring supply continuity, product quality, and long-term readiness for clinical and commercial success.

All Resources

Seamless Onshoring from China-Based CDMO to Avid Bioservices

Onshoring with Confidence

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content: